Introduction
Autoimmune diseases are characterized by the breakdown of immune tolerance leading to autoreactive immune mechanisms and consequential tissue and organ damages. In the pathogenesis of autoimmune diseases, various cellular and humoral immune processes have been described, including disproportional T and B cell responses, altered cytokine milieu and disturbed apoptotic processes, which result in exaggerated immune responses. In the last decades, a large amount of studies confirmed that B cell activation plays a crucial role in the inflammatory processes through antigen presentation, autoantibody production and secretion of numerous pro-inflammatory factors. However, In primary Sjögren's syndrome (pSS), which is a common systemic autoimmune disease characterized by chronic inflammation and consequential destruction of exocrine glands, humoral autoimmune responses, B cell activation and autoantibody production are key immune abnormalities, as well. Immunohistological analysis of biopsies from minor salivary glands commonly demonstrates the presence of ectopic GCs in pSS. The number of GCs in salivary glands correlates with the severity of inflammation, and anti-SSA/Ro and anti-SSB/La autoantibody-production. Moreover, the formation of ectopic GCs carries a higher risk of developing B cell lymphoma 5 .
Recently, we demonstrated elevated circulating CD4 + CXCR5 + ICOS + PD-1 + T FH cell percentages in pSS. Based on our data, we found a strong association between the T FH cell proportions and the presence of systemic extraglandular manifestations (EGMs) and 6 anti-SSA/SSB autoantibody positivity. Patients with higher T FH cell proportions also had elevated serum levels of IL-12 and IL-21 6 . Maehara et al. described that the expression of Th2 and certain T FH -related molecules was associated with robust lymphocytic accumulation and ectopic GC formation 7 . We also investigated the localization of T FH cells in the lymphocyte infiltration in labial salivary gland (LSG) biopsies gained from pSS patients at the time of disease onset, and found that T FH cell markers (CD84, PD-1, and Bcl-6) occurred predominantly in more organized lymphoid structures with higher focus scores 8 , which indicates that T FH cells may be good therapeutic targets in pSS, as well.
However, the complex interplay between T FH cells and the special subsets of B cells is not yet fully elucidated. Since identification of the pathogenic pathways and the corresponding biomarkers linking abnormal cellular activity to disease activity and outcome is essential for defining proper therapeutic targets, the aim of the present study was to profile the pathological connection between the peripheral T FH cells and B cell subsets and the clinical features of pSS and SLE.
7 10, 11 ; and their disease activity was assessed by the SLE Disease Activity Index (SLEDAI). SLE patients were classified according to having inactive or active disease status:
Materials and methods

Patients and healthy individuals
SLEDAI<6 group comprised subjects with inactive disease (n=17), while SLEDAI≥6 group consisted of subjects with active disease (n=8). All of the SLE patients received per os methylprednisolone therapy with an average dose of 4 mg daily; the dose of the treatment did not exceed 8 mg methylprednisolone per day in any case of SLE patients.
The blood samples were collected from SLE patients 24 hours after taking the regular methylprednisolone medication. The active disease status in the corresponding SLE patients was newly recognised, and these patients undergone the blood sampling before 8 any changes in their therapy. In addition, patients were also categorized according to their serological markers with a special emphasis on the presence of autoantibodies.
Among pSS patients, we found 9 anti-Ro/SSA positive (SSA>10 U/ml) individuals, 4 of them were anti-Ro/SSA -anti-La/SSB double positive. Regarding SLE patients, 15 of them were anti-dsDNA positive (dsDNA>20 IU/ml). 
Results
The distribution of peripheral B cell subpopulations
According to the expression of IgD, CD27, CD38 and CD24 cell surface markers, the (Fig. 1d) . Certainly, this tendency was also found in the remaining patient subgroups, however the differences were not significant. (Fig. 1f) .
Furthermore, the ratio of CD19 + CD38 + CD24 + B cells was also significantly elevated not only in the total SLE group, but in the SLEDAI>6 group compared to those measured in healthy subjects (35.86 ± 14.86% vs. 27.74 ± 9.33%, respectively, p=0.0297 and 39.32 ± 11.61% vs. 27.74 ± 9.33%, respectively, p=0.0094) (Fig. 1f) .
The ratio of peripheral CD19 + CD38 hi CD27 hi plasmablasts showed a different tendency in the two disease. The percentages of these cells were significantly lower in the overall group of pSS patient, as well as in the patients with EGMs groups than control values (0.134 ± 0.154% vs. 0.267 ± 0.293%, respectively, p=0.0050 and 0.127 ± 0.183% vs.
0.267 ± 0.293%, respectively, p=0.0014) (Fig. 1h) . However, in patients with SLE, we found significantly higher frequency of CD19 + CD38 hi CD27 hi plasmablasts only in SLEDAI>6 group compared to healthy subjects (1.150 ± 1.181% vs. 0.2671 ± 0.2932%, respectively, p=0.0403) (Fig. 1h) . (Fig. 2a) . The frequency of T FH -like cells was also elevated in SLE, however this difference was significant only when the overall SLE patients were compared with the controls (0.3369 ± 0.2029% vs, 0.2235 ± 0.0979%, respectively, p=0.0184) (Fig. 2a) . Additionally, we analysed the distribution of T FH cells percentages in the patient groups according to the absence or presence of specific autoantibodies. The ratio of T FH cells showed a significant 2-fold increase in anti-Ro/SSA antibody-positive group compared to healthy controls and anti-Ro/SSA antibody-negative group as well (0.4806 ± 0.2699% vs.
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0.2235 ± 0.0979%, respectively, p=0.0050 and 0.4806 ± 0.2699% vs. 0.2568 ± 0.1893%, respectively, p=0.0138) (Fig. 2b) . Regarding anti-dsDNA antibody-positive group, we found a significant 1.6-fold increase compared to control values (0.3717 ± 0.2153% vs. 0.2235 ± 0.0979%, respectively, p=0.0192) (Fig. 2b) .
We and we found a significant positive correlation in the whole measured group (R=0.6393, respectively, p=0.0010) (Fig. S2) .
Measurement of individual cytokine production of circulating T FH cells
To establish the cytokine profile of circulating T FH -like cells, we determined intracellular IL-21 cytokine production. 2c ). When we measured the percentages of T FH cells in patients with pSS with an emphasis on the presence of autoantibodies, the percentages of T FH cells showed a significant 1.8-fold increase in anti-Ro/SSA antibody-positive pSS group compared to controls (0.2742 ± 0.1418% vs. 0.1469 ± 0.0649%, respectively, p=0.0297) (Fig. 2d) . In SLE patients, we found significant 2. 0.2356 ± 0.1509%, respectively, p=0.0489) (Fig. 2d) (Fig. 3) .
Assessment of IL-10 producing B cells
As a next step, we cultured PBMCs for 5 h or 48 h, stimulated them with PIB alone or in combination with CpG, and then determined the ratios of IL-10 producing CD19 + B cells. After 5-hour incubation with PIB + CpG, we found no significant differences in the ratio of IL-10 + CD19 + B cells between patient groups and healthy controls (Fig. 4a) .
However, after 48 h incubation period and stimulation with PIB alone for the last 5 h, we found that the percentages of IL-10 + CD19 + B cells in the pSS patient group were significantly decreased than those measured in controls and SLE patient group (0.9688 ± 0.4284% vs. 1.592 ± 0.8799%, respectively, p=0.0076 and 0.9688 ± 0.4284% vs.
1.645 ± 1.198%, respectively, p=0.0127) (Fig. 4b) 1.645 ± 1.198%, respectively, p<0.0001) (Fig. 4b) . However, there were no significant differences between the patients groups and healthy controls regarding the distribution of IL-10 + CD19 + B cells after 48 h of CpG stimulation.
Correlation analysis between peripheral T FH -like cells and certain B cell subpopulations in pSS
We measured the relationship between the percentages of CD19 (Fig. 5c) . (Fig. 5d) . Furthermore, a significant negative correlation was found between the ratios of primarily memory B cells and T FH -like cells also in the same subgroup (R=-0.6317, respectively, p=0.0065) (Fig. 5e ). Of note, these differences were tendentiously observed in the whole SLE group as well, however the correlations were not significant (data not shown (Fig. 5f ). 20 We examined the possible relationship between circulating T FH -like cells or IL-21
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producing T FH -like cells and serological markers (Table 1) , moreover between certain B cell subsets and serological markers as well ( Table 2) .
Discussion
Patients with pSS and SLE are characterised by fundamental disturbances in the proportion of different B cell subpopulations, both in the peripheral blood and the site of inflammation. In our study, we found a significant enrichment of CD19 + IgD + CD27
naive B cells in the peripheral blood of both pSS and SLE patients compared to healthy individuals. This observation is consistent with previous reports [12] [13] [14] This discrepancy may arise from the heightened expression of CXCR3 and CXCR4 on plasma cells and plasmablast of patients with pSS, which leads to their migration toward the site of inflammation or even the bone marrow [29] [30] [31] . Moreover, in SLE, the differentiation toward plasmablasts is more pronounced, compared to pSS, and could be originated from both T-dependent and T-independent responses.
T FH cells are crucial immune regulators in secondary lymphoid follicles by controlling B cell proliferation and differentiation. Since the measurement of human GC T FH cell from lymphoid follicles could be hardly performed, the investigation of circulating T FHlike cells are widely accepted. In the last few years, a number of observations indicated that circulating T FH cells represent a partial differentiated state, however they express T FH -related markers at lower intensity and maintain functional characteristic to promote B cell differentiation 32, 33 . At the periphery, T FH -like cells may represent a memory CD4 + T cell condition, and according to certain cell surface molecules, including ICOS, PD-1 and CCR7, they can be subdivided into distinct subsets 34 .
In the present study, we revealed a significant increase in the proportion of peripheral CD4 + CXCR5
+ ICOS + PD-1 + T FH -like cells in pSS patients with EGMs compared to control values, while values of pSS patients without EGMs were similar to healthy individuals. Moreover, we also observed a significant difference between patients with and without EGMs. With this independent set of pSS cases, we reinforced our previous findings 6 . When we divided patients into subgroups based on the presence of anti-SSA/Ro, we found significantly higher T FH -like cell percentages in autoantibody positive group. The same changes were measured in SLE, and circulating T FH -like cell percentages were significantly elevated in patients positive for anti-dsDNA, however there was no significant difference between the inactive and active status of the disease.
As next step, we evaluated the proportion of IL-21 producing CD4 + CXCR5 + PD-1 + T FHlike cells and found a significant elevation in pSS patients with EGMs and/or anti-SSA/Ro positivity. Similarly, a marked expansion was observed in SLE patients, which was independent from the disease status, however the tendency was more pronounced in patients with anti-dsDNA autoantibody. Previous investigations on T FH -like cells led to similar results [35] [36] [37] [38] [39] [40] [41] , however the identification of these cell types are not fully 
